See also:

HOPE study, 2000	TRC3707
	download pdf: vitamin E | antioxydants for cardiovascular prevention

Treatments

Studied treatment	vitamin E 400IU/d from natural sources
Control treatment	matching placebo
Remarks	factorial design of ramipril and vitamin E

Patients

Patients	women and men 55 years of age or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor.
Baseline characteristics	Women (%) 6.7%

Method and design

Randomized effectives	4761 / 4780 (studied vs. control)
Design	Factorial plan
Blinding	double-blind
Follow-up duration	4.5y
Premature discontinuation	Premature discontinuation for futility
Number of centre	multicenter
Geographic area	Multinational: Canada, USA, Europe, South America
Hypothesis	Superiority
Primary endpoint	CV death, MI, stroke

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

Non fatal MI

532 / 4761
524 / 4780
1,02 [0,91;1,14]

Haemmorhagic stroke

17 / 4761
13 / 4780
classic 1,31 [0,64;2,70]

stroke (fatal and non fatal)

209 / 4761
180 / 4780
1,17 [0,96;1,42]

ischemic stroke

192 / 4761
167 / 4780
1,15 [0,94;1,41]

Cardiovascular death

342 / 4761
328 / 4780
1,05 [0,90;1,21]

cardiovascular events

772 / 4761
739 / 4780
1,05 [0,96;1,15]

Non fatal stroke

209 / 4761
180 / 4780
1,17 [0,96;1,42] 0 2 1.0

Relative risks
Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
	Studied treat.	Control treat.
stroke (fatal and non fatal)	209 / 4761 (4,4%)	180 / 4780 (3,8%)	1,17	[0,96;1,42]	BMJ 2010	13777
ischemic stroke	192 / 4761 (4,0%)	167 / 4780 (3,5%)	1,15	[0,94;1,41]		0
Cardiovascular death	342 / 4761 (7,2%)	328 / 4780 (6,9%)	1,05	[0,90;1,21]
cardiovascular events	772 / 4761 (16,2%)	739 / 4780 (15,5%)	1,05	[0,96;1,15]
Non fatal stroke	209 / 4761 (4,4%)	180 / 4780 (3,8%)	1,17	[0,96;1,42]
Haemmorhagic stroke	17 / 4761 (0,4%)	13 / 4780 (0,3%)	1,31	[0,64;2,70]		0
Non fatal MI	532 / 4761 (11,2%)	524 / 4780 (11,0%)	1,02	[0,91;1,14]
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 13777: Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth TEffects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials.BMJ 2010 Nov 4;341:c5702 0:

Endpoint	studied treat.	control treat.	mean diff

Absolute risk reduction (for a follow-up of 4.5y)
Endpoint	Events rate		Absolute risk reduction (ARR)
	Studied treat.	Control treat.
stroke (fatal and non fatal)	4,39%	3,77%	0,62%
ischemic stroke	4,03%	3,49%	0,54%
Cardiovascular death	7,18%	6,86%	0,32%
cardiovascular events	16,22%	15,46%	0,75%
Non fatal stroke	4,39%	3,77%	0,62%
Haemmorhagic stroke	3,57‰	2,72‰	0,09%
Non fatal MI	11,17%	10,96%	0,21%

Meta-analysis of all similar trials:

antioxydants in cardiovascular prevention for all type of patients

antioxydants in cardiovascular prevention for secondary prevention

Reference(s)

TrialResults-center ID	TRC3707
Trials register #	NA

• Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.. N Engl J Med 2000 Jan 20;342:154-60
  Pubmed | Hubmed | Fulltext
• Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.. JAMA 2005 Mar 16;293:1338-47
  Pubmed | Hubmed | Fulltext

(c) 2004-2016 TrialResults-center - All Rights Reserved